Q2 EPS Estimate for Aclaris Therapeutics Raised by Analyst

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Analysts at HC Wainwright raised their Q2 2026 EPS estimates for Aclaris Therapeutics in a research note issued on Monday, May 11th. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will post earnings per share of ($0.12) for the quarter, up from their prior estimate of ($0.13). HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Aclaris Therapeutics’ FY2026 earnings at ($0.49) EPS, Q4 2027 earnings at ($0.15) EPS and FY2027 earnings at ($0.51) EPS.

ACRS has been the subject of a number of other reports. Guggenheim initiated coverage on shares of Aclaris Therapeutics in a report on Tuesday, May 5th. They set a “buy” rating and a $12.00 price objective for the company. Oppenheimer assumed coverage on shares of Aclaris Therapeutics in a research report on Thursday, April 16th. They issued an “outperform” rating and a $10.00 price objective on the stock. Wall Street Zen lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, April 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Friday, March 27th. Finally, Wedbush boosted their price objective on shares of Aclaris Therapeutics from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Wednesday, April 29th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $11.29.

Aclaris Therapeutics Price Performance

Shares of NASDAQ ACRS opened at $4.88 on Wednesday. The stock has a market capitalization of $681.54 million, a P/E ratio of -8.71 and a beta of 0.76. The company has a 50-day moving average price of $3.94 and a 200-day moving average price of $3.32. Aclaris Therapeutics has a 1 year low of $1.16 and a 1 year high of $5.12.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. The business had revenue of $2.00 million during the quarter, compared to analysts’ expectations of $1.32 million. Aclaris Therapeutics had a negative net margin of 832.58% and a negative return on equity of 55.89%.

Institutional Investors Weigh In On Aclaris Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP raised its position in shares of Aclaris Therapeutics by 88.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 511,461 shares of the biotechnology company’s stock worth $1,914,000 after acquiring an additional 240,611 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Aclaris Therapeutics by 1.7% during the 1st quarter. Bank of New York Mellon Corp now owns 207,024 shares of the biotechnology company’s stock valued at $776,000 after acquiring an additional 3,507 shares during the last quarter. Strs Ohio purchased a new stake in shares of Aclaris Therapeutics during the 1st quarter valued at about $60,000. Assenagon Asset Management S.A. lifted its stake in shares of Aclaris Therapeutics by 14.7% in the 1st quarter. Assenagon Asset Management S.A. now owns 177,283 shares of the biotechnology company’s stock worth $665,000 after purchasing an additional 22,729 shares during the period. Finally, SG Americas Securities LLC raised its stake in Aclaris Therapeutics by 73.6% during the 1st quarter. SG Americas Securities LLC now owns 26,767 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 11,344 shares during the period. 98.34% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, major shareholder Braden Michael Leonard sold 300,000 shares of the company’s stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $4.53, for a total transaction of $1,359,000.00. Following the completion of the sale, the insider directly owned 13,950,000 shares in the company, valued at $63,193,500. This represents a 2.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 5.60% of the stock is owned by corporate insiders.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical?stage biopharmaceutical company focused on discovering, developing and commercializing novel small?molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non?melanoma skin lesions. Lead programs include ATI?50002, a topical agent in late?stage development for molluscum contagiosum removal; ATI?50003 for common wart resolution; ATI?1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI?450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.